查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930024

亨汀顿氏舞蹈症治疗市场规模、占有率、成长及全球产业分析：依药物、通路和地区划分的洞察与预测（2025-2034）

Huntington's Disease Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 133 Pages | 商品交期: 请询问到货日

价格

亨汀顿氏舞蹈症治疗市场成长驱动因素

到2025年，全球亨汀顿氏舞蹈症治疗市场规模达到13.9亿美元，这反映出人们对这种罕见进行性神经退化性疾病症状管理疗法的需求日益成长。预计到2026年，该市场规模将达到15.3亿美元，并在2034年成长至43.3亿美元，预测期内年复合成长率（CAGR）为13.9%。 市场成长得益于已开发地区疾病盛行率的上升、公众意识的增强以及针对新型治疗方法的研究活动的增加。

亨汀顿氏舞蹈症（HD）是一种遗传性疾病，患者脑内的神经细胞会逐渐退化，导致运动功能障碍、认知能力下降和精神障碍。虽然目前尚无治癒方法，但已核准的药物疗法可以有效控制舞蹈症及相关症状。目前，tetrabenazine、Deutetrabenazine和valbenazine是全球唯一核准用于治疗亨汀顿氏舞蹈症患者舞蹈症的药物。

市场成长驱动因素

市场成长的主要驱动因素是亨廷顿病患病率的上升，尤其是在北美和欧洲。预计到2023年，北美地区的发病率将达到每 10万人 8.87 例，欧洲将达到每 10万人 6.37 例，这将导致对治疗干预措施的持续需求。 中国和印度等新兴经济体诊断率的上升也进一步推动了治疗方案的普及。

另一个关键驱动因素是政府机构和研究组织积极参与提高公众意识和资助临床开发计画。公私合作和拨款资助加速目的是延缓疾病进展的临床试验。诊断意识的提高促使治疗更早启动，并扩大了目标患者群体。

市场限制因子

儘管成长前景良好，但市场面临着与长期用药相关的副作用挑战。已获批准的治疗药物，例如deutetrabenazine和valbenazine，都存在抑郁、自杀意念、镇静和心律不整等副作用的警告。这些安全问题可能会限制患者的用药依从性和处方模式，尤其是在弱势患者群体中。

此外，罕见疾病治疗药物严格的监管要求和漫长的审批流程可能会阻碍候选药物的快速商业化，并减缓新型疗法的市场渗透。

新兴市场趋势

亨汀顿氏舞蹈症治疗市场最显着的趋势之一是先进基因和分子疗法的涌现。这些疗法包括反义寡核苷酸（ASO）疗法、RNA干扰（RNAi）、CRISPR-Cas9基因编辑、锌指蛋白（ZFP）疗法以及基于TALEN的疗法。这些新一代疗法直接针对突变型亨汀顿氏舞蹈症（HTT）基因，目的是解决疾病的根本原因，而不仅仅是抑制症状。

不断增加的临床研究投入和早期试验的良好资料引起了投资者和机构投资者的极大兴趣，表明治疗策略正转向疾病修饰疗法。

市场区隔分析

依药物类型

依药物类型划分，tetrabenazine将在2025年占据市场主导地位，市场占有率将达到64.21%。其主导地位归功于它是首个获得FDA批准用于治疗亨廷顿氏症（HD）舞蹈症的药物，以及价格实惠的仿製药的供应。Deutetrabenazine因其更高的安全性以及每日一次的给药方式，将占据更大的市场占有率。valbenazine在近期获得监管部门批准用于治疗HD相关舞蹈症后，也备受关注。 "其他" 细分市场预计将快速成长，这得益于不断扩大的临床研发管线和尚未满足的医疗需求。

依通路划分

依通路划分，院内药房占据最大占有率，预计到2026年将占市场占有率的47.57%，这主要得益于医保覆盖、专家监督和住院治疗的需求。零售药局在处方续约方面仍将发挥关键作用，而线上药局预计将实现最快成长，这得益于数位化医疗的普及和送货上门的便利性。

区域洞察

北美地区凭藉着较高的疾病认知度、完善的医保体系和蓬勃发展的临床研究生态系统，预计将引领全球市场，2025年市场规模将达到11.6亿美元，2026年将达到12.7亿美元。光是美国一地预计在2025年就将占据12.2亿美元的市场。

欧洲占据了相当大的市场占有率，这主要得益于新型疗法的商业化努力和监管申报数量的增加。亚太地区崛起成为第二大市场，预计到2026年将达到1000万美元，这主要得益于战略联盟和已获批准药物可及性的提高。包括拉丁美洲和中东、非洲在内的其他地区，由于患病率较低和认知度有限，成长速度较慢，但展现出长期成长潜力。

这份全球亨汀顿氏舞蹈症治疗市场报告对2025年至2034年期间的产业进行了全面分析，其中2025年为基准年，2026年为估计年，2034年为预测年。报告评估了市场规模和价值趋势、成长前景以及影响亨汀顿氏舞蹈症治疗发展的结构性因素。

本研究依药物和通路进行了详细的细分，揭示了已获批准的治疗药物（例如tetrabenazine、Deutetrabenazine和valbenazine）在医院药房、零售药房和线上平台上的使用模式。区域分析涵盖北美、欧洲、亚太地区和世界其他地区，深入分析了各地区的疾病盛行率、治疗可近性、偿付环境和研究强度。

此外，本报告还探讨了市场驱动因素、限制因素、新兴趋势和在研药物的进展。 这包括基因和分子疗法的进展，例如反义寡核苷酸、RNA疗法和基因编辑方法。竞争格局部分评估了主要製药和生物技术公司的策略，重点是监管审批状态、临床试验进展、合作伙伴关係和新製剂上市。本报告还涵盖了COVID-19对诊断率、治疗可及性和商业表现的影响。

市场成长主要得益于已核准的舞蹈病治疗药物的广泛应用以及对下一代疾病修饰疗法的投资不断增加。儘管副作用和严格的监管要求等挑战仍然存在，但进行中的临床试验和政府主导的研究计划增强了市场的长期前景。

北美市场领先。这得归功于较高的认知度、健全的偿付体系和蓬勃发展的临床研究生态系统。欧洲和亚太地区紧随其后，不断扩大的治疗可及性和战略合作伙伴关係推动市场成长。总体而言，在科学技术进步、患者群体不断成长以及持续努力满足未被满足的需求的推动下，亨汀顿氏舞蹈症治疗市场有望实现长期强劲成长。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第4章 主要考察

  • 主要国家和地区亨廷顿病患病率（2025年）
  • 主要产业趋势（併购、新产品发表等）
  • 主要公司产品线分析
  • 各地区亨汀顿氏舞蹈症治疗的经济负担
  • 主要国家的监管和偿付情况区域
  • COVID-19 对全球亨汀顿氏舞蹈症治疗市场的影响

第5章 全球亨汀顿氏舞蹈症治疗市场分析、洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依药物类型划分
    • tetrabenazine
    • Deutetrabenazine
    • valbenazine
    • 其他
  • 市场分析、洞察与预测：依通路划分
    • 医院药房
    • 药局和零售药房
    • 线上药房
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 其他地区全球

第6章 北美亨汀顿氏舞蹈症治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第7章 欧洲亨汀顿氏舞蹈症治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区

第8章 亚太地区亨汀顿氏舞蹈症治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 亚太其他地区

第9章 世界其他地区亨汀顿氏舞蹈症治疗市场分析、洞察与预测（2021-2034）

第10章 竞争分析

  • 全球市场占有率分析（2025）
  • 公司简介
    • Teva Pharmaceutical Industries Ltd.
    • H. Lundbeck A/S
    • Bausch Health Companies Inc.
    • Neurocrine Biosciences, Inc.
    • Prilenia Therapeutics
    • Novartis AG
    • Lupin
    • Hikma Pharmaceuticals PLC
    • Dr. Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries, Inc.
Product Code: FBI107140

Growth Factors of Huntington's disease treatment Market

The global Huntington's disease treatment market was valued at USD 1.39 billion in 2025, reflecting the growing demand for symptom-management therapies for this rare and progressive neurodegenerative disorder. The market is projected to reach USD 1.53 billion in 2026 and further expand to USD 4.33 billion by 2034, exhibiting a CAGR of 13.9% during the forecast period. Market growth is supported by increasing disease prevalence in developed regions, rising awareness, and intensified research activities focused on novel therapeutic approaches.

Huntington's disease (HD) is a hereditary condition characterized by the gradual degeneration of nerve cells in the brain, resulting in motor dysfunction, cognitive decline, and psychiatric disturbances. Although no curative therapy exists, approved pharmacological treatments effectively manage chorea and associated symptoms. Currently, tetrabenazine, deutetrabenazine, and valbenazine remain the only globally approved drugs for the treatment of chorea in HD patients.

Market Growth Drivers

A key factor driving market expansion is the increasing prevalence of Huntington's disease, particularly in North America and Europe. According to 2023 estimates, disease prevalence reached 8.87 per 100,000 population in North America and 6.37 per 100,000 in Europe, leading to sustained demand for therapeutic intervention. Rising diagnosis rates in emerging economies such as China and India are further contributing to treatment adoption.

Another major driver is the growing involvement of government bodies and research organizations in funding awareness and clinical development programs. Public-private collaborations and grant funding are accelerating clinical trials aimed at modifying disease progression. Increased diagnostic awareness has resulted in earlier treatment initiation, thereby expanding the addressable patient population.

Market Restraints

Despite favorable growth prospects, the market faces challenges related to adverse effects associated with long-term drug use. Approved therapies such as deutetrabenazine and valbenazine carry warnings related to depression, suicidal ideation, sedation, and cardiac irregularities. These safety concerns may limit patient compliance and prescribing patterns, especially in vulnerable populations.

Additionally, stringent regulatory requirements and lengthy approval timelines for rare-disease drugs pose barriers to rapid commercialization of pipeline candidates, potentially slowing market penetration of novel therapies.

Emerging Market Trends

One of the most prominent trends in the Huntington's disease treatment market is the emergence of advanced genetic and molecular therapies. These include antisense oligonucleotide (ASO) therapies, RNA interference (RNAi), CRISPR-Cas9 gene editing, zinc-finger protein (ZFP) therapies, and TALEN-based approaches. These next-generation modalities aim to target the mutant huntingtin (HTT) gene directly, addressing the root cause of the disease rather than symptom control alone.

Increasing clinical research initiatives and positive early-phase trial data are attracting significant investor and institutional interest, signaling a shift toward disease-modifying strategies.

Segmentation Analysis

By Drug

Based on drug type, tetrabenazine dominated the market, accounting for 64.21% share in 2025. Its dominance is attributed to being the first FDA-approved treatment for HD chorea and the availability of cost-effective generic versions. Deutetrabenazine held a significant share due to improved safety and once-daily formulations, while valbenazine gained traction following recent regulatory approvals for HD-associated chorea. The "others" segment is expected to grow rapidly due to an expanding clinical pipeline and unmet therapeutic needs.

By Distribution Channel

By distribution channel, hospital pharmacies held the largest share and are projected to account for 47.57% of the market in 2026, supported by insurance coverage, specialist supervision, and inpatient treatment requirements. Retail pharmacies continue to play a vital role in prescription refills, while online pharmacies are anticipated to register the fastest growth due to digital healthcare adoption and home delivery convenience.

Regional Insights

North America dominated the global market, valued at USD 1.16 billion in 2025 and USD 1.27 billion in 2026, driven by high disease awareness, strong reimbursement frameworks, and active clinical research ecosystems. The U.S. alone accounted for USD 1.22 billion in 2025.

Europe represented a significant share, supported by increasing commercialization efforts and regulatory submissions for new therapies. Asia Pacific emerged as the second-largest market, projected to reach USD 0.01 billion in 2026, with growth driven by strategic partnerships and improved access to approved drugs. The rest of the world, including Latin America and the Middle East & Africa, showed slower growth due to lower prevalence and limited awareness but presents long-term expansion potential.

Competitive Landscape

The market is led by Teva Pharmaceutical Industries Ltd., driven by strong adoption of its AUSTEDO formulations. Other key players include Neurocrine Biosciences, Inc., H. Lundbeck A/S, Prilenia Therapeutics, and Novartis AG. Continuous product development, regulatory approvals, and global collaborations remain central to competitive strategy as companies seek to address the unmet needs in Huntington's disease treatment.

Report Coverage

The global Huntington's disease treatment market report provides a comprehensive analysis of the industry for the period 2025 to 2034, with 2025 as the base year, 2026 as the estimated year, and 2034 as the forecast year. The report evaluates market size and market value trends, growth outlook, and structural developments influencing the evolution of Huntington's disease therapeutics.

The study covers detailed segmentation by drug type and distribution channel, highlighting adoption patterns of approved therapies such as tetrabenazine, deutetrabenazine, and valbenazine across hospital pharmacies, retail pharmacies, and online platforms. Regional analysis spans North America, Europe, Asia Pacific, and the rest of the world, offering insights into disease prevalence, treatment accessibility, reimbursement environments, and regional research intensity.

In addition, the report examines market drivers, restraints, emerging trends, and pipeline developments, including advances in genetic and molecular therapies such as antisense oligonucleotides, RNA-based treatments, and gene-editing approaches. The competitive landscape section assesses the strategies of leading pharmaceutical and biotechnology companies, focusing on regulatory approvals, clinical trial progress, partnerships, and new formulation launches. The report also incorporates the impact of COVID-19 on diagnosis rates, treatment access, and commercial performance.

Conclusion

The global Huntington's disease treatment market demonstrated steady expansion in 2025, reaching a market value of USD 1.39 billion, supported by increasing disease prevalence, rising diagnostic awareness, and sustained demand for symptom-management therapies. Continued growth to USD 1.53 billion in 2026 and a projected value of USD 4.33 billion by 2034 reflects strong momentum driven by clinical innovation and expanding research activity.

Market growth is primarily supported by the widespread use of approved chorea-management drugs and increasing investment in next-generation disease-modifying therapies. While challenges such as adverse drug reactions and stringent regulatory requirements remain, ongoing clinical trials and government-backed research initiatives are strengthening long-term market prospects.

Regionally, North America maintains market leadership due to high awareness levels, strong reimbursement frameworks, and an active clinical research ecosystem, followed by Europe and Asia Pacific, where expanding access to therapies and strategic partnerships are supporting growth. Overall, the Huntington's disease treatment market is positioned for robust long-term expansion, driven by scientific advancements, rising patient identification, and continued efforts to address significant unmet clinical needs.

Segmentation By Drug

  • Tetrabenazine
  • Deutetrabenazine
  • Valbenazine
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug, Distribution Channel, and Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Drug, Distribution Channel, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Rest of the World (By Drug and Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Huntington's Diseases, Key Countries/ Regions, 2025
  • 4.2. Key Industry Developments (Mergers, Acquisitions, New Product Launches, etc.)
  • 4.3. Pipeline Analysis, Key Players
  • 4.4. Economic Cost Burden for the Treatment of Huntington's Disease, By Regions
  • 4.5. Regulatory & Reimbursement Scenario, By Key Regions
  • 4.6. Impact of COVID-19 on the Global Huntington's Disease Treatment Market

5. Global Huntington's Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. Tetrabenazine
    • 5.1.2. Deutetrabenazine
    • 5.1.3. Valbenazine
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.2.1. Hospital Pharmacies
    • 5.2.2. Drug Stores & Retail Pharmacies
    • 5.2.3. Online Pharmacies
  • 5.3. Market Analysis, Insights and Forecast - By Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Rest of the World

6. North America Huntington's Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. Tetrabenazine
    • 6.1.2. Deutetrabenazine
    • 6.1.3. Valbenazine
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.2.1. Hospital Pharmacies
    • 6.2.2. Drug Stores & Retail Pharmacies
    • 6.2.3. Online Pharmacies
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Huntington's Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. Tetrabenazine
    • 7.1.2. Deutetrabenazine
    • 7.1.3. Valbenazine
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.2.1. Hospital Pharmacies
    • 7.2.2. Drug Stores & Retail Pharmacies
    • 7.2.3. Online Pharmacies
  • 7.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 7.3.1. U.K.
    • 7.3.2. Germany
    • 7.3.3. France
    • 7.3.4. Spain
    • 7.3.5. Italy
    • 7.3.6. Rest of Europe

8. Asia Pacific Huntington's Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. Tetrabenazine
    • 8.1.2. Deutetrabenazine
    • 8.1.3. Valbenazine
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.2.1. Hospital Pharmacies
    • 8.2.2. Drug Stores & Retail Pharmacies
    • 8.2.3. Online Pharmacies
  • 8.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.3.1. Japan
    • 8.3.2. China
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. Rest of Asia Pacific

9. Rest of the World Huntington's Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. Tetrabenazine
    • 9.1.2. Deutetrabenazine
    • 9.1.3. Valbenazine
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.2.1. Hospital Pharmacies
    • 9.2.2. Drug Stores & Retail Pharmacies
    • 9.2.3. Online Pharmacies

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Teva Pharmaceutical Industries Ltd.
      • 10.2.1.1. Overview
      • 10.2.1.2. Products & services
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. H. Lundbeck A/S
      • 10.2.2.1. Overview
      • 10.2.2.2. Products & services
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Bausch Health Companies Inc.
      • 10.2.3.1. Overview
      • 10.2.3.2. Products & services
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. Neurocrine Biosciences, Inc.
      • 10.2.4.1. Overview
      • 10.2.4.2. Products & services
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Prilenia Therapeutics
      • 10.2.5.1. Overview
      • 10.2.5.2. Products & services
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Novartis AG
      • 10.2.6.1. Overview
      • 10.2.6.2. Products & services
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Lupin
      • 10.2.7.1. Overview
      • 10.2.7.2. Products & services
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Hikma Pharmaceuticals PLC
      • 10.2.8.1. Overview
      • 10.2.8.2. Products & services
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)
    • 10.2.9. Dr. Reddy's Laboratories Ltd.
      • 10.2.9.1. Overview
      • 10.2.9.2. Products & services
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. Financials (Based on Availability)
    • 10.2.10. Sun Pharmaceutical Industries, Inc.
      • 10.2.10.1. Overview
      • 10.2.10.2. Products & services
      • 10.2.10.3. SWOT Analysis
      • 10.2.10.4. Recent Developments
      • 10.2.10.5. Strategies
      • 10.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 2: Global Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 3: Global Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 4: North America Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 5: North America Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 6: North America Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 7: Europe Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 8: Europe Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 9: Europe Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 10: Asia Pacific Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 11: Asia Pacific Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 12: Asia Pacific Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 13: Rest of the World Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 14: Rest of the World Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034

List of Figures

  • Figure 1: Global Huntington's Disease Treatment Market Value Share (%), By Drug, 2025 & 2034
  • Figure 2: Global Huntington's Disease Treatment Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 3: Global Huntington's Disease Treatment Market Value (USD billion), By Region, 2025 & 2034
  • Figure 4: North America Huntington's Disease Treatment Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 5: North America Huntington's Disease Treatment Market Value Share (%), by Drug, 2025
  • Figure 6: North America Huntington's Disease Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 7: North America Huntington's Disease Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 8: North America Huntington's Disease Treatment Market Value (USD billion), by Country, 2025 & 2034
  • Figure 9: North America Huntington's Disease Treatment Market Value Share (%), by Country, 2025
  • Figure 10: Europe Huntington's Disease Treatment Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 11: Europe Huntington's Disease Treatment Market Value Share (%), by Drug, 2025
  • Figure 12: Europe Huntington's Disease Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 13: Europe Huntington's Disease Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 14: Europe Huntington's Disease Treatment Market Value (USD billion), by Country/ Sub-Region, 2025 & 2034
  • Figure 15: Europe Huntington's Disease Treatment Market Value Share (%), by Country/ Sub-Region, 2025
  • Figure 16: Asia Pacific Huntington's Disease Treatment Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 17: Asia Pacific Huntington's Disease Treatment Market Value Share (%), by Drug, 2025
  • Figure 18: Asia Pacific Huntington's Disease Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Asia Pacific Huntington's Disease Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Asia Pacific Huntington's Disease Treatment Market Value (USD billion), by Country/ Sub-Region, 2025 & 2034
  • Figure 21: Asia Pacific Huntington's Disease Treatment Market Value Share (%), by Country/ Sub-Region, 2025
  • Figure 22: Rest of the World Huntington's Disease Treatment Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 23: Rest of the World Huntington's Disease Treatment Market Value Share (%), by Drug, 2025
  • Figure 24: Rest of the World Huntington's Disease Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 25: Rest of the World Huntington's Disease Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 26: Global Huntington's Disease Treatment Market Share Analysis (%), By Company, 2025